Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Werewolf weighs sale or merger as cash reserves whimper

Werewolf weighs sale or merger as cash reserves whimper

  • February 24, 2026

With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. The immuno-oncology outfit is weighing a full range of strategic options, including selling or merging the company, with the goal of giving shareholders the biggest bang for their buck.

Leave A Comment

Fields (*) Mark are Required